Management of the PD patient: From diagnosis
to advanced disease

Oksana Suchowersky, MD,

Module 1: The de novo Parkinson disease patient

Module 2: The Parkinson disease patient at 5-10 years

Module 3: The Parkinson disease patient at 10-15 years

Module 4: Advanced Parkinson disease (15+ years)

Introduction

Oksana Suchowersky, MD, Professor & Director, Movement Disorders Program, University of Calgary, provides presentation on the longitudinal management of the Parkinson disease patient from diagnosis and management of early disease to advance stages of this disorder, spanning a period of over 20 years. Her presentation complements previous presentations in the AMAprimarycare.org_Parkinson disease program that address different aspects of both motor and non-motor disease management, and different stages of disease.

Intended Audience

This continuing medical education program is intended for primary care physicians and other healthcare professionals who manage patients with Parkinson's disease.

Educational Objectives

After completing this activity, participants should be better able to:

Describe the diagnostic criteria for Parkinson disease
Distinguish rest tremor of Parkinson disease from essential tremor
Describe the treatments for the newly diagnosed patient
List the motor complications seen with disease progression (5-10 years)
Recognize what non-motor symptoms occur in advanced Parkinson disease
Review the motor complications in advanced disease (10-15 years)
Explain when surgical treatment should be considered
Review the treatment of motor symptoms in advanced Parkinson disease (+15 years)
List the new non-motor symptoms (eg dementia, depression) in advanced Parkinson disease
Describe the health care planning for the patient with advanced Parkinson disease

Information on CME credit

The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Medical Association designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nonphysicians may receive a certificate of participation for completing this activity.

Instructions for CME credit

This online enduring material is presented as a video webcast, featuring a clinical exchange, with attendant slide presentation. To receive credit, please view all of the presentations of this CME activity and evaluate the content presented. Complete both the pre- and post-test and activity evaluation.

The estimated time to complete this activity, including pre-test, review of the materials, and self-assessment and evaluation is 1.5 hours.

Principal Faculty

William J. Weiner, MD, Planning Committee Chair, Content Reviewer
Professor of Neurology
Chair, Department of Neurology
Director, Maryland Parkinson's Disease and Movement Disorder Center
University of Maryland School of Medicine
Baltimore, MD

Shobha S. Rao, MD, Planning Committee, Content Reviewer
Assistant Professor
Family and Community Medicine
Departments of Geriatric and Family Medicine
University of Texas Southwestern Medical School
Dallas, TX

Kathleen M. Shannon, MD, Planning Committee, Content Reviewer
Associate Professor, Neurological Sciences
Department of Neurology
Rush Movements Disorders Group
Rush-Presbyterian-St. Luke's Medical Center
Rush Medical College
Chicago, IL

Oksana Suchowersky, MD, FRCPC, FCCMG, Planning Committee, Author/Presenter
Professor and Head
Department of Medical Genetics
Director, Movement Disorders Program
University of Calgary
Calgary, AB, Canada

R. Mark Evans, PhD, Planning Committee
Director, Healthcare Education Products and Standards
American Medical Association
Chicago, IL

Kristi Eidsvoog, PhD, Planning Committee
Content Manager
MedEd Architects, LLC
Chicago, IL

Patti Fitzgerald, Planning Committee
Manager, Product Development, Healthcare Education Products and Standards
American Medical Association
Chicago, IL

Disclosure Policy

In order to assure the highest quality of CME programming, and to comply with the ACCME Standards for Commercial Support, the AMA requires that all faculty and planning committee members disclose relevant financial relationships with any commercial or proprietary entity producing health care goods or services relevant to the content being presented. We therefore obtain a completed disclosure and attestation form to inform the participant of any pertinent relationships disclosed, provided here.

These materials have been peer-reviewed by the members of the the AMAprimarycare Parkinson Disease Planning Committee to ensure the continued scientific accuracy and medical relevance of information presented and its independence from commercial bias. The AMA has control over all final content.

Dr. Rao: Nothing relevant to disclose

Dr. Shannon: Research Support, Kyowa, Schwarz, Teva, Schering/Titan; Consultant, Valeant, Prestwick

Dr. Suchowersky: Speaker's Bureau, Teva, Novartis; Advisory Board, Teva, Novartis

Dr. Weiner: Advisory Board, Novartis; Research Support, Boehringer-Ingelheim, Teva; Speaker's Bureau, Teva

Dr. Evans: Nothing relevant to disclose

Dr. Eidsvoog: Nothing relevant to disclose

Ms. Fitzgerald: Nothing relevant to disclose

Acknowledgement of Support

This CME publication was supported through an independent education grant from Teva Neuroscience and produced in accordance with the AMA Standards for Industry-Supported Multimedia Continuing Medical Education and Other Communications.